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Abstract
From an epidemiological point of view, hepatitis E is an old
infection in Iran, but only recently has its importance as a
public health concern been considered from research and
public health standpoints. As such, there is still a long road
ahead to clarify the real burden of hepatitis E virus (HEV)
infection in Iran. According to the available epidemiological
studies, the seroprevalence of HEV infection among pregnant
women is between 3.6% and 7.4%, and among Iranian
children is between 0.9% to 8.5%, varying by geographic
regions within the country and directly dependent upon the
sanitary status of each. In addition to evaluating the sani-
tation level of a society, community-based seroprevalence
studies of HEV infection demonstrate the most prevalent risk
factors, the major routes of transmission, and the epidemio-
logical patterns of HEV among that country’s population. In
this review, the current knowledge about the pathogenesis
and epidemiology of HEV infection in pregnant women and
children in Iran, as well as the recent advances in diagnosis,
prevention and treatment of HEV infection have been sum-
marized.
© 2016 The Second Affiliated Hospital of Chongqing Medical
University. Published by XIA & HE Publishing Inc. All rights
reserved.
Introduction
Hepatitis E virus (HEV) infection is generally an enterically
transmitted viral hepatitis with asymptomatic or acute self-
limited manifestations.1 However, progression to fulminant
liver failure has also been reported in high-risk groups, such
as pregnant women and patients with underlying liver prob-
lems.1–7 Chronicity is rare and is mostly observed in immu-
nocompromised and immunosuppressed patients, such as
patients who have received organ transplant, are infected
with human immunodeficiency virus (HIV) or suffer from hae-
matological malignancies.5,8–14 Therefore, despite the benign
clinical presentation of hepatitis E in the general population,
it is considered as an important health concern, especially in
those high-risk populations.
According to the epidemiological data, 3.3 million acute
cases and 20 million new cases of hepatitis E are diagnosed
each year globally.3,15 Despite the mortality rate of 1–2% in
the general population,16 10–25% of pregnant women and
>75% of patients with underlying liver disease lose their
lives due to the HEV infection.17,18 According to a report
from the World Health Organization (WHO), ;56600 deaths
occur per year due to HEV-related hepatic failure.19 Overall,
one-third of the world’s population has been infected with
HEV.20,21
HEV is a small virus in the family Hepeviridae, with a
positive single-stranded RNA genome and non-enveloped ico-
sahedral capsid.5,9,22,23 The genome consists of three parti-
ally overlapping open reading frames (Fig. 1).5,24,25 HEV is
usually transmitted via the faecal-oral route, particularly
through contaminated food and water supplies. However,
transmission through haemodialysis, organ transplantation,
sexual intercourse, placenta, blood and blood product trans-
fusion is also possible, but the importance of each is
unknown.1,17,26 Only four genotypes capable of affecting
human beings have been identified thus far.3,27 These four
genotypes have been classified into the genus Orthohepevi-
rus and the species Orthohepevirus A,1,28 and they differ in
their mode of transmission, pathogenicity, severity, mortality
rates, geographical and age distribution.1,17,26,29,30
Genotypes 1 and 2 affect human beings and are responsible
for large epidemics or acute outbreaks in developing countries.
These outbreaks occur due to contamination of drinking water
following heavy rainfall or flooding, and are more frequently
observed among young adult males.1,3,5,13,26,29,31 Meanwhile,
genotypes 3 and 4 use an animal reservoir and are mostly
transmitted via consumption of contaminated meat; these
two genotypes are the causative agents of locally-acquired
sporadic HEV infections in developed countries and mostly
affect middle-aged to elderly males.1,3,5,13,29,31–33 These
variations in the epidemiological patterns of HEV reflect dif-
ferences in the level of sanitation, lifestyle, risk factors and
status of public health in the different groups and regions
across the globe.14,34–36 Therefore, it is important to study
the epidemiological patterns of hepatitis E in the different
groups and regions to determine the burden of this viral
infection.
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In Iran, HEV infection is endemic, but the epidemiology of
this infection in two of the most vulnerable groups—pregnant
women and children—remains unclear. Therefore, this study
was conducted to provide a general overview of the patho-
genesis and epidemiology of hepatitis E in these two groups
in Iran.
HEV in pregnant women in Iran
HEV infection is not only generally a benign self-limited
disease, but it can also adversely affect pregnant women
and lead to fulminant hepatic failure, especially during the
second and third trimesters, subsequently lowering survival
of mothers and their fetuses.37–41 Overall, it is reported that
0% to 73% of mortalities in pregnant women are attributed to
HEV infection in the endemic regions, representing 0% in
Egypt, 3.4% in South India, 42% in Ethiopia and 39.1–73%
in North India.39 Besides maternal complications, HEV also
causes serious consequences to the foetus following transpla-
cental transmission, which varies in severity from low birth
weight, prematurity, mild anicteric neonatal hepatitis or jaun-
dice at birth with full recovery to miscarriage, stillbirth,
preterm labour, perinatal death or neonatal death soon after
birth.1,27,29,37,38,40,42 No extrahepatic manifestations or
chronic carrier state has been reported in children born to
mothers with HEV infection.27,38
Such severe complications in pregnancy are not seen with
the other known hepatitis viruses.5,22,40 Although the exact
mechanism of this excess severity of hepatitis E in pregnancy
has not yet been determined, it seems that a combination of
host and viral factors contributes to the pathogenesis of hep-
atitis E during pregnancy.1,37,39
Pregnancy is accompanied by significant changes in
maternal hormonal and immunological responses to sustain
the foetus.39,40 These immunological changes include inhibi-
tion of cell-mediated immunity through secretion of trans-
forming growth factor-beta (TGF-b) and IL-4 and IL-10
cytokines, down-regulation of nuclear factor-kappa B (NF-kB),
reduction in T cell activity and cytokine production, along
with an alteration in cellular immune regulation towards
an increase in CD8 cell counts and a decrease in CD4 cells
with predominant T helper 2 (Th2) responses; all of these
result in systematic suppression of the maternal immune
system and subsequently increase susceptibility to infec-
tions.1,37,39,40 Moreover, the steroid hormones including
beta-HCG (human chorionic gonadotropin), oestrogen and
progesterone increase during pregnancy.5,39,40,42 These
hormones have direct inhibitory effects on hepatocytes,
cell-mediated immunity, T helper 1 (Th1) cell development
and B cell production; moreover, through the decreased
expression of NF-kB, they promote lymphocyte apoptosis.
In addition, these hormones induce viral replication and the
development of Th2 cells.37,39,40,42
Although the above-mentioned hormonal and immunolog-
ical changes physiologically occur in normal pregnancy, when
pregnancy is accompanied by HEV infection these changes
increase.39,40,42 As such, HEV-infected pregnant women may
suffer from decreased activity or absence of the p65 compo-
nent of the NF-kB complex, which likely induces acute liver
damage.39,40 Moreover, HEV appears to have a direct cytopa-
thogenic effect on hepatic cells or immune-mediated patho-
genesis through induction of host inflammatory responses,
which may result in destruction of hepatocytes.1,43 Although
Th2 responses are predominant in normal pregnancy, a
strong cytotoxic immune response may be induced through
an alteration in T helper responses towards Th1 following HEV
infection aimed at reducing the high viral load, but which in
turn results in lower foetal survival rates.42
Fig. 1. Molecular structure of hepatitis E virus.1 (Adapted from Fig. 1 of reference 1, with permission of the publisher).
Abbreviations: M, methyltransferase; Y, Y domain; P, papain-like cysteine protease; HVR, hypervariable region; X, macro-domain; H, helicase; RdRp, RNA-dependent RNA
polymerase; Triangle, glycosylation site.
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Foetal infection with HEV will enhance the severity of
infection and risk of liver failure in the mother.38–40 Moreover,
the inhibitory effects of steroid hormones on hepatocytes can
result in hepatic dysfunction when pregnancy is accompanied
by HEV infection.40,42 Overall, it seems that HEV by itself does
not induce these changes and requires pregnancy as a phys-
iological factor to enhance the risk of hepatic damage. There-
fore, pregnant women with hepatitis E are at an increased risk
for developing liver failure.39,40
It seems that viral load and genotype can influence
severity of HEV infection during pregnancy. As such, high
viral load, along with genotypes 1 and 2, known as the more
virulent genotypes, contribute to the development of fulmi-
nant liver failure (FLF).1,5,37,38,42 In addition, poor maternal
nutrition and the use of herbal medicines to relieve symptoms
of HEV infection due to side effects are associated with
increased severity of hepatitis E.39,40,42,43 Finally, the role of
genetic factors, such as variation in human leukocyte antigen
(HLA) alleles in different geographical regions, should also be
considered in the pathogenesis of HEV infection during
pregnancy.39,40
An endotoxin-mediated effect has been proposed as
another probable factor in the pathogenesis of FLF in preg-
nancy. In this process, the Kupffer cells, a type of liver
sinusoidal cells, are destroyed by HEV, negating their ability
to protect the liver cells against endotoxin derived from gram-
negative bacteria of the intestinal tract.40 In addition, release
of prostaglandins due to HEV infection can indirectly damage
hepatocytes through attraction of neutrophils, which result in
inflammation, oedema and cholestasis in liver.40
In endemic regions, the incidence and severity of HEV
infection in pregnant women are much higher than that in
non-pregnant women and men, with reported maternal
mortality rates of 30–100% in the various studies.1,39,40,44
The rate of vertical transmission from mother to foetus
varies from 30% to 79%, and sometimes up to 100%, in
the different studies as well.27 In addition, mother-to-child
transmission via breastfeeding is also possible and mostly
occurs during the acute phase of infection.37 In developing
countries, HEV infection accounts for approximately 3000
stillbirths annually.5,37 Interestingly, the above-mentioned
epidemiological pattern is not observed in all endemic coun-
tries.5,44 In Egypt, for example, despite reporting high sero-
prevalence of HEV among pregnant women, the disease
follows a mild or asymptomatic course, with very low mortal-
ity.38–40,44 However, the exact reason behind this benign
pathogenicity remains unclear, but might be related to the
presence of a highly contagious but less virulent strain of
the HEV genotype predominantly found in Egypt5,22,38–40,44
or possibly the differences in major histocompatibility
complex (MHC) phenotypes in this country as compared to
the other endemic areas.5 It can also be explained by the
high levels of previous exposure to HEV in early childhood,
resulting in long-lasting immunity and probably attenuated
infection upon re-exposure to HEV in adulthood.5,38–40
Similar findings have been reported in the United States
(US) and Europe, where there is no difference in the severity
of HEV infection in pregnant women compared to that in non-
pregnant women,38,39,42 while HEV seroprevalence is consid-
erably high but most HEV infections are asymptomatic or
remain undiagnosed.44
In Iran, however, the epidemiology is even more unclear.
There are few reports on the seroprevalence of HEV infection
among pregnant women in Iran. In the available studies,
however, the seroprevalence of HEV infection varies from
3.6% to 7.6%,45–49 which is more or less similar to HEV sero-
prevalence in the general population of Iran (Table 1 and
Fig. 2). Moreover, age, level of education, parities, stage of
gestation and the number of family members have been iden-
tified as risk factors for HEV seropositivity among these
reported pregnant women.46–48 In particular, increasing ges-
tational age, lower education, third trimester of pregnancy
and more parities are associated with high seroprevalence
of HEV infection among the pregnant women.46–48 Compared
to the other endemic countries,50–52 the seroprevalence of
HEV infection among Iranian pregnant women is low.45,47,48
In addition, there is a considerable difference in rate of HEV
seroprevalence between Iran and neighbouring countries
such as the United Arab Emirates (20.0%)53 and India
(33.67%);50 meanwhile, it is similar to that reported for
Turkey (7.0%).54
Considering the adverse effects of HEV infection on preg-
nancy outcomes, prevention strategies, appropriate precau-
tions and training programs regarding the possible routes of
exposure to HEV as well as routine screening for HEV infection
before and during pregnancy are needed to reduce the
occurrence and adverse consequences of HEV infection in
the pregnant population.46,47 Overall, the importance of HEV
infection during pregnancy is underestimated in Iran and
there are no current data on the rate of maternal mortality
in Iran.
HEV in children in Iran
There are few studies on the seroprevalence of HEV infection
among children in Iran. In those studies, seroprevalence
rates vary from 0.9% to 8.5% (Table 1 and Fig. 2).55–59
Although the seroprevalence of HEV among children in Iran
is not as high as reported for Nepal (16%), Tibet (23.8%) and
India (17.75%–24.7%),27 it is still considerably higher than
for Taiwan (0.3%), Mongolia (0.6%), Greenland (0.0%),
Korea (0%–1%) and Argentina (0.15%).27 Globally, the
highest HEV prevalence, ranging from 36.2% to 75.5%, has
been reported for children in Egypt.27
The sero-epidemiological patterns of HEV infection among
children in Iran are similar to those observed in other endemic
countries, such as Bangladesh, Mexico, China, Turkey and
Venezuela.27 Those studies have shown that the HEV seropre-
valence is low in early childhood but increases with
age.27,55,57 Egypt is an exception, with the majority of chil-
dren being exposed to HEV in early life, as evidenced by 65%
of children under 10 years of age being seropositive.27,60
Globally, <10% of children aged under 10 years are HEV
seropositive.27
Most cases of HEV infection among children are subclin-
ical.27,39,55 Despite this asymptomatic feature, the mortality
rate is considerably high in children with jaundice; one study
in Uganda reported a high mortality rate among icteric chil-
dren, which was even higher than the mortality rates reported
among the pregnant women in that country.16 However, there
is no report on the mortality rate of HEV infection among chil-
dren in Iran.
Some studies have evaluated the trends in seroprevalence
of HEV infection among children over time and showed a
slight but not significant increase in HEV seropositivity. One
study from India indicated a significant increase in HEV
seroprevalence over time.27 However, due to inadequate
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studies in Iran, the changes in trends of HEV seroprevalence
over time remain unclear.
Children are representative of a group at risk of HEV
infection.27 Recent studies have shown that the seropreva-
lence of HEV infection among children is related to sanitary
status of different parts of the country.55,61 Considering the
fact that contaminated drinking water supplies and inappro-
priate sewage disposal systems are associated with HEV sero-
positivity, the faecal-oral route is the main route of HEV
transmission among Iranian children.55 Therefore, age-specific
community-based seroprevalence studies of HEV infection are
used to describe the sanitation level and public health status of
a society. Overall, these studies have indicated that children in
Iran are exposed to HEV and, therefore, preventive strategies
are needed to reduce this exposure.55–57
Diagnosis of HEV infection
HEV causes a vast range of clinical presentations, which vary
in severity from FLF, liver fibrosis and cirrhosis following
chronic hepatitis E, and acute icteric hepatitis to unapparent
and asymptomatic infection.1,7,9,15,29,62 Most cases of hepa-
titis E among children are asymptomatic,27,39 and no cases of
chronic hepatitis E have been reported in pregnant women
and infants.38 Chronic HEV infection is, however, frequently
observed among immunocompromised and immunosup-
pressed patients.7,9,14,29
The clinical manifestations of HEV infection are indistin-
guishable from clinical symptoms of the other viral hepatitis
forms.35 In addition, these non-specific symptoms some-
times mask the diagnosis of HEV infection, making laboratory
methods the most reliable criteria for diagnosis. The labora-
tory diagnosis methods are based on detection of HEV RNA in
serum or stool samples by nucleic acid amplification techni-
ques (NAT) or of anti-HEV antibodies in serum or plasma
samples by serological tests (Fig. 3).1,5,17,63–65
The presence of HEV RNA in blood and stool is short-lived,
and becomes undetectable in serum at 3–4 weeks and in stool
at 6 weeks after the onset of clinical symptoms (Fig. 4).17,29
In asymptomatic subjects, viremia can last for 4–6 weeks.17
However, a prolonged viremia is also possible, especially
among children following acute HEV infection and immuno-
suppressed patients.4,17 Anti-HEV IgM increases during the
acute phase of infection. IgM level remains high for about 8
weeks, but declines rapidly and becomes undetectable in
most patients after 3–8 months.5,27 Meanwhile, long-lasting
anti-HEV IgG antibodies appear shortly after the increase of
IgM and persist for 1–14 years or more after the infection
Fig. 2. Map of Iran.
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(Fig. 4).5,29,63 Thus, detection of IgM is indicative of acute
infection, and the presence of IgG is a sign of previous expo-
sure to HEV.1,29
Evaluation of liver parameters is another diagnostic crite-
rion. At onset of clinical symptoms, liver function tests show
abnormal findings, such as for themeasurements of aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphate, gamma-glutamyl transpeptidase and
bilirubin.22,62 However, elevated levels of liver enzymes are
short-lived and return to normal about 6 weeks after the
onset of clinical symptoms.27
Prevention and treatment of HEV infection
The current preventive strategies primarily aim at reducing
exposure to HEV by improving water supply facilities and
sewage disposal systems, since the disease is predominantly
transmitted via the faecal-oral route.17 Therefore, provision of
safe water supplies, sanitary preparation of food, sanitary dis-
posal of human waste and hygienic infrastructure appear to
be the most effective preventive measures.1,5,22,30,37,66
Vaccination against HEV is another preventive strategy,
although no commercial vaccine has yet become available
worldwide.17 Several HEV vaccines have been designed and
evaluated in the laboratory setting, including recombinant
vaccines consisting of various truncated forms of the capsid
protein (HEV 239,67 trpE-C2,68 53 kDa,69 pE2,70 56 kDa,69
rHEVVLP,71 62 kDa72 and T1-ORF273), DNAvaccines (pcHEVORF2
and Lipo-NE-DP74–76) and, more recently, epitope-based vac-
cines.18,77 Amongst them, only one recombinant vaccine, the
HEV 239 vaccine based on a 26 kDa portion of the HEV capsid
protein (aa 368–606), has been licensed by China’s State
Food and Drug Administration.3,18,78–81 Yet, this vaccine,
despite showing promising results in human clinical trials, is
not still approved for use in a susceptible population such as
pregnant women, children and patients with pre-existing liver
problems, and is not available worldwide.16,18,78
Upon disease emergence, the treatment strategy is usually
supportive, as the disease is generally asymptomatic or self-
limited at this stage.9,17,82 Antiviral treatment is administered
only for patients with hepatic complications due to fulminant or
chronic HEV infection.9,17 These antiviral therapies include
monotherapy with pegylated interferon (PEG-IFN) or ribavirin,
or combination therapy with these antiviral agents.9,82,83
Although these antiviral treatments result in clearance of the
Fig. 3. Laboratory diagnosis of hepatitis E virus infection.38 (Adapted from
Fig. 3 of reference 38, with permission of the publisher).
Fig. 4. Virological markers of hepatitis E virus infection.38 (Adapted from Fig. 2 of reference 38, with permission of the publisher).
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virus and reduction of the symptomatic period, they harbour
their own limitations and side effects.26,83,84 PEG-IFNa has
neuropsychiatric side effects and induces influenza-like symp-
toms, and ribavirin causes impaired renal function and
anemia.83–85 Above all, these antiviral agents have teratogenic
effects during pregnancy.9,38,84 Therefore, termination of
pregnancy or early delivery of the foetus seems to be the
most effective option to save mothers.38,39
Conclusions
This review has provided a general overview of the patho-
genesis and epidemiology of HEV infection in pregnant women
and children in Iran. HEV infection is generally a benign self-
limited disease, but it can lead to serious consequences in
susceptible populations such as pregnant women. It seems
that a combination of host and viral factors contributes to the
pathogenesis of hepatitis E in pregnancy; although, the exact
reason behind this excess severity during pregnancy is not yet
fully understood.
HEV infection is an underestimated disease in Iran, most
probably due to a lack of HEV consideration in the country’s
public health system. Despite being prevalent among children
and pregnant women, our current knowledge regarding
epidemiology of this viral infection in Iran is scarce. There-
fore, further studies are required to more comprehensively
determine the incidence and prevalence of HEV infection in
these two groups in different regions of Iran. Once these data
are obtained, the epidemiological pattern of this neglected
infection in Iran will become clearer.
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